Dosage protocol · Bioregulators
Livagen 20 mg
Typical daily range: 0.5–2.0 mg once daily (gradual titration over 8–12 weeks).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Typical daily range: 0.5–2.0 mg once daily (gradual titration over 8–12 weeks).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 0.0667 mg (66.7 mcg) on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Reconstitution
Livagen dosage chart
| Week | Dose | Draw |
|---|---|---|
| Weeks 1–2 | 0.5 mg500 mcg | 7.5 units0.075 mL |
| Weeks 3–4 | 1.0 mg1000 mcg | 15 units0.15 mL |
| Weeks 5–6 | 1.5 mg1500 mcg | 22.5 units0.225 mL |
| Weeks 7–12 | 2.0 mg2000 mcg | 30 units0.30 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Livagen is a synthetic tetrapeptide built from four amino acids — lysine, glutamic acid, aspartic acid, and alanine — often abbreviated KEDA and listed in PubChem as H-Lys-Glu-Asp-Ala-OH.[1] It belongs to a category researchers call peptide bioregulators: short peptides studied mainly in Russian and Eastern European laboratories for possible effects on gene activity and cellular aging.
Livagen is not an approved medicine, a hormone, or a growth-factor drug. It is best understood as a laboratory research compound with a fairly narrow, specialized literature centered on chromatin biology, immune cells, and a handful of organ-culture studies.
Benefits & side effects
Livagen's evidence base is built almost entirely from laboratory and ex vivo work rather than patient trials. Key studies include chromatin decondensation and ribosomal gene activation in lymphocytes taken from older adults, ranging from age 75 to 88 in one study.[2][3] A separate human-serum assay found that Livagen inhibited enkephalin-degrading enzymes with an IC50 of about 20 micromolar, while showing no measurable binding to opioid receptors in rat brain tissue.[7]
Additional findings come from rat hepatocyte cultures examining protein-synthesis rhythms and a rat study of oral Livagen affecting digestive-enzyme activity differently in young versus old animals.[8][10] These are informative laboratory and animal results, not evidence of benefit in humans. No randomized controlled human trial measuring patient-level outcomes — symptoms, organ function, survival, or quality of life — appears in the literature reviewed for Livagen.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.